BMC Neurology .
Current Availability and Regulatory Status in the UK Retatrutide is not approved for clinical use in the UK as of April 2025 and can only be accessed through MHRA-registered clinical trials
DA: Writing original draft, Formal analysis
as described by Falanga and colleagues, TfR is expressed highly in bone marrow, immune system, and female tissues, moderately in brain, endocrine tissues, lung, gastrointestinal tract, kidney, urinary bladder, male tissues, and skin, and low in muscle tissues, liver, gallbladder, adipose, and soft tissue, aside from serum [21]
all doses of semaglutide marketed under the trade names Ozempic and Wegovy became listed as available on the FDAs Drug Shortage List as of October 30, 2024